BioNTech, the German pharmaceutical company that teamed with Pfizer to develop the first widely used COVID-19 vaccine, on Wednesday reported strong
quarterly earnings growth on pandemic-fueled demand.
The company posted net profit of nearly $3.6 billion for the final three months of 2021, up from $409 million in the same period the previous year.
Quarterly revenue rose to $6.1 billion from $384 million previously.
Vaccinations with the Pfizer-BioNTech vaccine, marketed as Comirnaty, started in December 2020. BioNTech, based in the city of Mainz near Frankfurt, said about 2.6 billion doses of the vaccine had been delivered last year.
